BR112015023105A2 - construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a? - Google Patents

construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?

Info

Publication number
BR112015023105A2
BR112015023105A2 BR112015023105A BR112015023105A BR112015023105A2 BR 112015023105 A2 BR112015023105 A2 BR 112015023105A2 BR 112015023105 A BR112015023105 A BR 112015023105A BR 112015023105 A BR112015023105 A BR 112015023105A BR 112015023105 A2 BR112015023105 A2 BR 112015023105A2
Authority
BR
Brazil
Prior art keywords
peptide
constructs
immunogen
individual
peptide immunogen
Prior art date
Application number
BR112015023105A
Other languages
English (en)
Other versions
BR112015023105A8 (pt
Inventor
Yi Wang Chang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR112015023105A2 publication Critical patent/BR112015023105A2/pt
Publication of BR112015023105A8 publication Critical patent/BR112015023105A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

abstract the present disclosure is directed to individual aß peptide immunogen constructs, peptide compositions comprising these aß peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aß peptide immunogen constructs, with the individual aß peptide immunogen constructs having the n-terminus of the aß peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aß peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease. tradução do resumo resumo título: vacina peptídica para prevenção e imunoterapia de demência advinda de alzheimer a presente invenção refere-se a construtos peptídeo imunógeno aß individuais, composições peptídicas compreendendo estes construtos peptídeo imunógeno aß e misturas dos mesmos, composições farmacêuticas incluindo formulações de vacina compreendendo esses construtos peptídeo imunógeno aß, com os construtos peptídeo imunógeno aß individuais tendo o n-terminal do peptídeo aß, tal como os epítopos da célula b (b) ligados através de resíduo(s) espaçador heterólogo para epítopos (th) de células t helper derivados de proteínas patogênicas que atuam em conjunto para estimular a produção de anticorpos altamente específicos direcionados contra o n-terminal do peptídeo aß oferecendo respostas imunes protetoras para pacientes em risco de, ou com, a doença de alzheimer.
BR112015023105A 2013-03-15 2013-04-23 construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo. BR112015023105A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Publications (2)

Publication Number Publication Date
BR112015023105A2 true BR112015023105A2 (pt) 2017-11-21
BR112015023105A8 BR112015023105A8 (pt) 2018-01-23

Family

ID=51527985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023105A BR112015023105A8 (pt) 2013-03-15 2013-04-23 construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.

Country Status (19)

Country Link
US (4) US9102752B2 (pt)
EP (1) EP2968485B1 (pt)
JP (3) JP6208319B2 (pt)
KR (2) KR101926030B1 (pt)
CN (2) CN105228644B (pt)
AU (3) AU2013381835A1 (pt)
BR (1) BR112015023105A8 (pt)
CA (1) CA2906313A1 (pt)
DK (1) DK2968485T3 (pt)
ES (1) ES2800028T3 (pt)
HK (1) HK1212600A1 (pt)
IL (2) IL241597B (pt)
MX (2) MX364689B (pt)
PT (1) PT2968485T (pt)
RU (1) RU2696566C2 (pt)
SG (1) SG11201507669YA (pt)
TW (1) TWI561529B (pt)
WO (1) WO2014143087A1 (pt)
ZA (2) ZA201507526B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US9315545B2 (en) * 2014-04-07 2016-04-19 Merganser Biotech, Inc. Hepcidin mimetic peptides and uses thereof
KR101901669B1 (ko) 2016-01-27 2018-09-28 경상대학교산학협력단 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물
CN109072274A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体（aspd）样结构体及医药组合物
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
BR112019026707A2 (pt) * 2017-06-16 2020-06-30 United Neuroscience imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias
EP3700558A4 (en) 2017-10-27 2022-03-09 United Neuroscience TAU PEPTIDE IMMUNOGEN CONSTRUCTS
JP7250032B2 (ja) * 2017-12-11 2023-03-31 ユービーアイ アイピー ホールディングス アトピー性皮膚炎の治療及び／または予防のためのｉｌ－３１のペプチド免疫原ならびにその製剤
RU2769983C2 (ru) * 2017-12-31 2022-04-12 Юнайтед Байомедикал, Инк. ПЕПТИДНЫЕ ИММУНОГЕНЫ И СОДЕРЖАЩИЕ ИХ СОСТАВЫ, НАЦЕЛЕННЫЕ НА МЕМБРАНОСВЯЗАННЫЕ IgE ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ IgE АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ
CA3091020A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
EP3790581A4 (en) * 2018-05-04 2022-06-22 UBI IP Holdings ARTIFICIAL PROMISCUOUS T-HELPER CELL EPITOPS THAT ENABLE TARGETED ANTIBODY PRODUCTION WITH LIMITED T-CELL INFLAMMATORY RESPONSE
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
CN113329762A (zh) * 2018-12-19 2021-08-31 美国联合生物医学公司 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
KR20210110842A (ko) * 2018-12-28 2021-09-09 유나이티드 바이오메디칼 인크. 인터루킨 6(il-6)을 표적화하는 펩타이드 면역원 및 il-6 조절장애에 의해 영향을 받는 질환의 면역요법을 위한 이의 제형
MX2021008035A (es) * 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
TWI823051B (zh) * 2020-01-23 2023-11-21 美商聯合生物醫學公司 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
IL296322A (en) 2020-03-10 2022-11-01 Lifearc Cyclic peptides
EP4247397A1 (en) * 2020-11-17 2023-09-27 Iliad Biotechnologies, LLC Treatment and prevention of neuropathology associated with neurodegenerative diseases
EP4307988A1 (en) * 2021-03-16 2024-01-24 NeuroVision Imaging, Inc. Biofluid-based methods for diagnosing alzheimer's disease-associated conditions
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
CA2175579A1 (en) 1993-10-26 1995-05-04 Chang Yi Wang Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
WO2001042306A2 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
EP1992639A4 (en) * 2006-02-22 2009-08-26 Hayashibara Biochem Lab PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AMYLOID ANTI-PEPTIDE ANTIBODIES
JP5161796B2 (ja) * 2006-02-24 2013-03-13 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 抗アミロイド免疫原性組成物、方法、および使用
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
AT509611B1 (de) 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
EP2342356A4 (en) * 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8916387B2 (en) * 2010-10-28 2014-12-23 Jonas Nilsson Diagnosis and treatment of Alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
KR20180132962A (ko) 2018-12-12
ZA201507526B (en) 2019-12-18
JP2016513638A (ja) 2016-05-16
US20190194280A1 (en) 2019-06-27
TWI561529B (en) 2016-12-11
CN108794615A (zh) 2018-11-13
IL241597B (en) 2020-07-30
RU2696566C2 (ru) 2019-08-05
AU2019246916A1 (en) 2019-10-31
JP2017226646A (ja) 2017-12-28
TW201434478A (zh) 2014-09-16
EP2968485B1 (en) 2020-03-04
RU2019123453A (ru) 2019-09-10
KR20150132396A (ko) 2015-11-25
EP2968485A4 (en) 2016-09-07
AU2017203425B2 (en) 2019-07-11
KR101926030B1 (ko) 2018-12-10
BR112015023105A8 (pt) 2018-01-23
CA2906313A1 (en) 2014-09-18
EP2968485A1 (en) 2016-01-20
HK1212600A1 (zh) 2016-06-17
MX364689B (es) 2019-05-06
JP6208319B2 (ja) 2017-10-04
ZA201906683B (en) 2023-04-26
AU2013381835A1 (en) 2015-10-08
US9102752B2 (en) 2015-08-11
US20160068581A1 (en) 2016-03-10
DK2968485T3 (da) 2020-06-08
JP2019196397A (ja) 2019-11-14
ES2800028T3 (es) 2020-12-23
CN105228644B (zh) 2018-07-13
CN105228644A (zh) 2016-01-06
US20180244739A1 (en) 2018-08-30
PT2968485T (pt) 2020-06-26
US20140271690A1 (en) 2014-09-18
SG11201507669YA (en) 2015-10-29
IL265910A (en) 2019-06-30
AU2017203425A1 (en) 2017-06-08
MX2019005268A (es) 2019-07-01
MX2015013235A (es) 2016-04-04
WO2014143087A1 (en) 2014-09-18
RU2015142996A (ru) 2017-04-24
JP6784646B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
BR112015023105A2 (pt) construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?
BR112019010972A2 (pt) receptores de células t e imunoterapia usando os mesmos
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
BR112016015422A2 (pt) formulações de vacina de frasco único
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
BR112015032713A2 (pt) composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
EP2542571A4 (en) OLIGOMER SPECIFIC BETA AMYLOID EPITOPE AND ANTIBODIES
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
BR112018067946A8 (pt) Formulações tópicas contendo ciclosporina e usos das mesmas
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária
BR112017013574A2 (pt) conjugados de aminoácido e peptídeo e usos dos mesmos
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
IN2014DN09445A (pt)
MX2015012461A (es) Proteinas sintéticas autoensamblables.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX2019007924A (es) Vacunas contra la influenza.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]